Receive news by e-mail

#
 

Enter your e-mail in the field below to receive directly the news that appears on this page.

 

topics : related - all Explore

Shopping Categories

  1. 1. Cell Phones
  2. 2. Smartphones
  3. 3. Digital Cameras
  4. 4. Laptop Computers
  5. 5. Processors
  6. 6. Motherboards
  7. 7. LCD Monitors
  8. 8. Graphics Cards
  9. 9. GPS
  10. 10. Digital Camcorders
  11. 11. Printers
  12. 12. Desktop Computers
  13. 13. Sedans
  14. 14. Coupes & Convertibles
  15. 15. 4x4

Wikio Shopping

  1. 1. Automotive
  2. 2. Beauty & Fragrances
  3. 3. Books
  4. 4. Car/Motorbike
  5. 5. CD
  6. 6. Clothing, Accessories & Shoes
  7. 7. Communication
  8. 8. Computers
  9. 9. DVD
  10. 10. Electronics
  11. 11. Flowers & Gifts
  12. 12. Gourmet & Foods
  13. 13. Health & Personal Care
  14. 14. Home & Garden
  15. 15. Hotels
  16. 16. Household Appliances
  17. 17. Jewelry & Watches
  18. 18. Musical Instruments
  19. 19. Sports & Outdoors
  20. 20. Toys & Baby
  21. 21. Video Games

Participate



Humira



Sort by : relevance - date
5Vote!

TNF-alpha Inhibitors, Most Notably Humira and Remicade, Will Continue to Dominate the Crohn's Disease Drug Market

WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira...

5Vote!

Humira and Nutrition Sales Lift Abbott 3Q Profit

Abbott Labs profit tops forecasts on greater Humira sales, raises 2009 profit view

+Vote!

Humira and nutrition sales lift Abbott 3Q profit

Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.

5Vote!

Humira and nutrition sales lift Abbott 3Q profit

Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.

5Vote!

Humira and nutrition sales lift Abbott 3Q profit

Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children. The North Chicago company says strong sales of Humira, an... Sponsored Topics: Abbott Laboratories - Adalimumab - Nutrition - Business - Health

5Vote!

Humira and nutrition sales lift Abbott 3Q profit

ABBOTT PARK, Ill. -- Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.

9Vote!

Humira and nutrition sales lift Abbott 3Q profit

Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.

5Vote!

Abbott Labs profit tops forecasts on greater Humira sales, raises 2009 profit view

Medical products revenue increased after Abbott bought eye care products maker Advanced Medical Optics in February. That deal contributed $263 million in revenue in the third quarter. Sales of molecular diagnostic products rose 15 percent to $82 million. Sales of stents also increased, but revenue from lab diagnostic products and diabetes care items decreased.

3Vote!

Humira and nutrition sales lift Abbott 3Q profit

ABBOTT PARK, Ill. — Abbott Laboratories says it beat its own expectations in the third quarter...

4Vote!

Humira and nutrition sales lift Abbott 3Q profit

Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.

5Vote!

Abbott profit rises on Humira demand, special gain

NEW YORK (Reuters) - Abbott Laboratories Inc on Wednesday said third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and Xience heart stent and gains from a settlement with Medtronic Inc .

5Vote!

Humira and nutrition sales lift Abbott 3Q profit

Abbott Laboratories says it beat its own expectations in the third quarter as sales of its drug Humira continued to climb, as did sales of medical products and nutritional products for children.

5Vote!

Humira sales a boost to Abbott

... Wall Street analysts' estimates.Abbott said sales of its blockbuster rheumatoid arthritis drug Humira, which also treats other autoimmune disorders, were up nearly 24 percent worldwide, to $1.5 billion. "That's really what investors are concerned about: What's the Humira growth rate?" First American Funds analyst Tim Nelson said. "I was looking for $1.3 billion, and they did $1.5...

5Vote!

Abbott profit up 37% on patent settlement, Humira sales

... 3.5 percent to $7.76 billion.Abbott said its sales of the blockbuster rheumatoid arthritis drug Humira, which also treats other autoimmune disorders, were up nearly 24 percent worldwide to $1.5 billion, an increase of nearly 24 percent from the prior year. The company said those sales were ahead of analyst expectations."Abbott is performing well, generating higher-than-expected earnings...

3Vote!

Anyone Taking Humira For Treatment Rheumatoid Arthritis?

I suffer from Rheumatoid arthritis and have several medicatins, one of which is Humira. I have taken this for 6 months. Has anyone taken this medication and had improvement in [...]